CLINDAMYCIN PHOSPHATE
Clinical safety rating: safe
May enhance the effects of neuromuscular blocking agents Causes severe and sometimes fatal Clostridium difficile-associated diarrhea.
Clindamycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.
| Metabolism | Hepatic metabolism primarily via CYP3A4 to active and inactive metabolites; some metabolism via non-CYP pathways. |
| Excretion | Renal 10% unchanged, fecal/biliary 90% as metabolites (mostly inactive) |
| Half-life | Terminal half-life 2-4 hours (prolonged to 8-12 hours in severe hepatic impairment; unchanged in renal failure) |
| Protein binding | 90-95% bound primarily to albumin |
| Volume of Distribution | 0.6-1.2 L/kg (wide distribution, penetrates most tissues except CNS; accumulates in bone and abscesses) |
| Bioavailability | Oral: 30-50% (dose-dependent); IM: 85-90% |
| Onset of Action | Oral: 0.5-1 hour; IM: 1-2 hours; IV: rapid (within minutes) |
| Duration of Action | Oral: 6-8 hours; IM: 8-12 hours; IV: 6-8 hours (bacteriostatic; duration can vary with dose and infection site) |
| Action Class | Lincosamides |
| Brand Substitutes | Acneclin Gel, Clinof Gel, Clincitop Gel, Aclind Gel, Camyda Gel |
600 mg IV every 8 hours or 300-450 mg PO every 6 hours
| Dosage form | GEL |
| Renal impairment | No dose adjustment required for GFR >30 mL/min; for GFR <30 mL/min, no adjustment needed but monitor for accumulation with high doses. |
| Liver impairment | Child-Pugh A/B: no adjustment; Child-Pugh C: reduce dose by 50% or use with caution. |
| Pediatric use | 10-25 mg/kg/day IV in 3-4 divided doses or 8-20 mg/kg/day PO in 3-4 divided doses; maximum dose 1800 mg/day IV. |
| Geriatric use | No specific dose adjustment; use lower end of dosing range due to potential renal impairment and increased risk of adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
May enhance the effects of neuromuscular blocking agents Causes severe and sometimes fatal Clostridium difficile-associated diarrhea.
| FDA category | Human |
| Breastfeeding | Clindamycin is excreted into human breast milk in low levels (M/P ratio approximately 0.5-1.0). The American Academy of Pediatrics considers it compatible with breastfeeding. However, caution is advised due to potential for gastrointestinal effects (e.g., diarrhea, candidiasis) in the nursing infant. |
| Teratogenic Risk |
■ FDA Black Box Warning
Clindamycin can cause severe, sometimes fatal, Clostridium difficile-associated diarrhea (CDAD).
| Serious Effects |
Hypersensitivity to clindamycin, lincomycin, or any component; history of antibiotic-associated colitis; pseudomembranous colitis.
| Precautions | Clostridium difficile-associated diarrhea (CDAD), hypersensitivity reactions, severe skin reactions (e.g., Stevens-Johnson syndrome), neuromuscular blocking effects, colitis, prolonged use leading to superinfection, hepatic impairment, renal impairment. |
Loading safety data…
| Clindamycin phosphate is classified as FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, and there are no adequate and well-controlled studies in pregnant women. Use only if clearly needed. No known teratogenic effects in first trimester; potential for alteration of neonatal gut flora if used near term. |
| Fetal Monitoring | Monitor maternal liver function tests and renal function periodically. Observe for signs of pseudomembranous colitis. In prolonged therapy, monitor blood counts. Fetal monitoring is not typically required; assess fetal heart rate patterns if used during labor for group B streptococcus prophylaxis. |
| Fertility Effects | No known adverse effects on fertility in animal studies. No human data indicate significant impact on fertility. |